LMAT LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About LeMaitre Vascular (NASDAQ: LMAT)
›
LeMaitre Vascular (NASDAQ: LMAT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 646 employees.
The shares were at 75.92 USD on 20 November 2026, down 11.9% over 52 weeks. Its 52-week range is 73.68 USD to 118.01 USD: the price is 35.7% below the high and 3.0% above the low.
At a market capitalisation of 1.71B USD, it trades at 27.2 times trailing earnings and 23.8 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 45% for LMAT. It pays a dividend yielding 1.32% (it pays out 35% of its earnings), against a median of 0.92% among the dividend payers in that peer group.
LeMaitre Vascular reports return on equity of 14.7%, an operating margin of 24.7% and revenue up 11.3% year over year.
It holds more cash than debt, a net cash position of 200.87M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 99.29 USD is 30.8% above the current price. The next earnings report is expected on 24 February 2027.